Ongoing high-throughput genomic studies may identify additional drivers/modifiers of GIST biology that can be targeted. Clinical genotyping of GISTs is important to identify KIT exon 9-mutant tumors that require a higher dose of imatinib for optimal disease control. Further, there are other molecular...
Clinical severity, type of FSHD, presence of modifiers, degree of D4Z4 hypomethylation, and location of muscle involvement must all be considered during stratification. 7. DUX4-Independent Approaches Incapacitating DUX4 and halting pathology are the primary goals of most therapeutic programs for ...